SCHEMBL335469

SCHEMBL335469

O=C(O)c1cccc2ncccc12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NSD2 O96028 1/20 0.60
ACLY P53396 1/20 0.58
KDM4E B2RXH2 6/20 0.57
TDP1 Q9NUW8 1/20 0.57
L3MBTL1 Q9Y468 3/20 0.55
MAPT P10636 3/20 0.55
ALDH1A1 P00352 3/20 0.55
CYP3A4 P08684 1/20 0.55
ALOX15 P16050 1/20 0.55
TSHR P16473 1/20 0.55
BLM P54132 1/20 0.55
AGER Q15109 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
KDM4A O75164 2/20 0.54
EGLN1 Q9GZT9 2/20 0.54
KDM6B O15054 1/20 0.54
KDM6A O15550 1/20 0.54
TET3 O43151 1/20 0.54
KDM4B O94953 1/20 0.54
KDM5C P41229 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29550511 1.00 NSD2 (0.60) NSD2ACLYKDM4ETDP1L3MBTL1
SCHEMBL28727190 0.98 NSD2 (0.59) NSD2ACLYKDM4ETDP1L3MBTL1
SCHEMBL5680479 0.98 NSD2 (0.59) NSD2ACLYKDM4ETDP1L3MBTL1
Hydrochloric Acid SCHEMBL5450942 0.98 NSD2 (0.59) NSD2ACLYKDM4ETDP1L3MBTL1
SCHEMBL5680469 0.98 NSD2 (0.59) NSD2ACLYKDM4ETDP1L3MBTL1
Formaldehyde SCHEMBL27690889 0.96 NSD2 (0.57) NSD2ACLYKDM4ETDP1L3MBTL1
Acetic Acid SCHEMBL27656229 0.95 NSD2 (0.56) NSD2ACLYKDM4ETDP1L3MBTL1
Aziridine SCHEMBL27648195 0.92 NSD2 (0.54) NSD2ACLYKDM4ETDP1L3MBTL1
Alcohol SCHEMBL28316967 0.92 NSD2 (0.57) NSD2ACLYKDM4ETDP1L3MBTL1
Quinoline SCHEMBL27803388 0.92 NR4A1 (0.58) NSD2ACLYKDM4ETDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 638 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122013223-A Bimetallic MOFs catalyst for synthesizing ammonia through electrocatalytic nitrate reduction and preparation method and application thereof 东华大学 2026-05-12 CN claimed
WO-2025202864-A1 ENT1 INHIBITORS IN COMBINATION WITH ONCOLYTIC VIRUSES AND THEIR USE IN THE TREATMENT OF CANCER iTeos Belgium SA (BE) 2025-10-02 WO claimed
WO-2025126110-A1 ENT1 INHIBITORS IN COMBINATION WITH BISPECIFIC ANTIBODIES iTeos Belgium SA (BE) 2025-06-19 WO claimed
CN-119735483-B Ethylene gas treatment method, polyolefin elastomer and preparation method thereof 合肥中科科乐新材料有限责任公司 2025-05-30 CN claimed
WO-2025104613-A1 ENT1 INHIBITORS IN COMBINATION WITH CHECKPOINT INHIBITORS iTeos Belgium SA (BE) 2025-05-22 WO claimed
CN-119841727-A Method for directly preparing carboxylic ester compound from aromatic aldehyde, ketone and carboxylic acid 湖南第一师范学院 2025-04-18 CN claimed
CN-119735483-A Ethylene gas treatment method, polyolefin elastomer and preparation method thereof 合肥中科科乐新材料有限责任公司 2025-04-01 CN claimed
CN-117797299-B Bacteriostatic agent, bacteriostatic paper diaper and preparation method of bacteriostatic paper diaper 杭州千芝雅卫生用品有限公司 2024-11-22 CN claimed
EP-4405369-A2 A CIS-PLATINUM(II)-OLIGOMER HYBRID Dublin City University (IE) 2024-07-31 EP claimed
US-20240246060-A1 Method Of Manufacture And Scale-Up Of The Metal-Organic Framework Cu(Qc)2 ExxonMobil Technology and Engineering Company 2024-07-25 US claimed
WO-2008152099-A2 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-12-18 WO claimed
WO-2008081399-A2 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2008-07-10 WO claimed
US-20080153837-A1 Novel Fluorene Derivatives, Composition Containing Said Derivatives and the Use Thereof AVENTIS PHARMA S.A. (FR) 2008-06-26 US claimed
CN-100393720-C Cyclic benzimidazoles. ALTANA PHARMA AG (DE) 2008-06-11 CN claimed
US-20070185148-A1 M3 muscarinic acetylchoine receptor antagonists GLAXO GROUP LIMITED (GB) 2007-08-09 US claimed
EP-1725238-A2 M 3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS GLAXO GROUP LIMITED (GB) 2006-11-29 EP claimed
CN-1784401-A Novel fused triazolones and uses thereof ASTRAZENECA AB (SE) 2006-06-07 CN claimed
WO-2005094251-A2 M3MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS GLAXO GROUP LIMITED (GB) 2005-10-13 WO claimed
US-20030044399-A1 Method of treatment SMITHKLINE BEECHAM CORPORATION 2003-03-06 US claimed
CN-1047081-A Antiseptic-germicide is with the manufacture method of composition and wherein used pyrroloquinoline derivative OTSUKA PHARMA CO LTD (JP) 1990-11-21 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030044399-A1 Method of treatment DNPEP, PEPD, ANPEP NSD2 2962/4885ACLY 826/4885KDM4E 956/4885
US-20070185148-A1 M3 muscarinic acetylchoine receptor antagonists CHRM3, CHRM2, CHRM5 NSD2 3459/4885ACLY 724/4885KDM4E 4650/4885
US-20080153837-A1 Novel Fluorene Derivatives, Composition Containing Said Derivatives and the Use Thereof HSP90B1, HSP90AB1, HSP90AA1 NSD2 2475/4885ACLY 3509/4885KDM4E 3419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.